{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:25:58Z","timestamp":1766748358145},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the Fund project from the Lianyungang Health Committee","award":["201715"],"award-info":[{"award-number":["201715"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Maintenance treatment after first-line chemotherapy for patients with metastatic colorectal cancer (mCRC) is a priority strategy. However, which medicine is chosen is controversial. This study aimed to determine the efficacy and safety of maintenance treatment with metronomic capecitabine vs observation.<\/jats:p>\n            <jats:p>In this randomized controlled trial, patients who completed 18 weeks of induction chemotherapy with XELOX and achieved disease control were randomly assigned centrally (1:1) to receive maintenance therapy with metronomic chemotherapy or observation until disease progression. The primary endpoint was progression-free survival from randomization; secondary endpoints included overall survival and safety. Analyses were performed by intention to treat.<\/jats:p>\n            <jats:p>Between January 1st, 2017 and December 31th 2018, 48 patients were enrolled and randomly assigned to receive maintenance treatment with metronomic capecitabine (n\u200a=\u200a25) or only observation (n\u200a=\u200a23). The median progression-free survival in the metronomic capecitabine group was 5.66 (95% confidence interval [CI] 5.25\u20136.07) months vs 3.98 (95%CI 3.71\u20134.24) months in the observation group (hazard ratio 0.11, 95% [CI] 0.04\u20130.26, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000). There was no statistically significant difference in median overall survival: 23.82 (95% CI 22.38\u201325.25) months in the metronomic capecitabine group vs 21.81 (95% CI 20.23\u201323.38) months in the observation group (hazard ratio 0.49, 95% CI 0.21\u20131.11, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.087). Subgroup analyses were generally consistent with the primary finding. Similar safety profiles were observed in both arms. The most frequent adverse events in metronomic capecitabine group included neutropenia, diarrhea, hand-foot skin reaction, and mucositis.<\/jats:p>\n            <jats:p>Maintenance therapy with metronomic capecitabine can be considered an alternative option following first-line chemotherapy of XELOX in patients with metastatic colorectal cancer with controlled toxicities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023719","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T21:48:42Z","timestamp":1608241722000},"page":"e23719","source":"Crossref","is-referenced-by-count":11,"title":["Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Rui","family":"Geng","sequence":"first","affiliation":[{"name":"School of Public Health, Nanjing Medical University, Nanjing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of gastrointestinal surgery, the Second People's Hospital of Lianyungang, Lianyungang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of gastrointestinal surgery, the Second People's Hospital of Lianyungang, Lianyungang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of gastrointestinal oncology, the Second People's Hospital of Lianyungang, Lianyungang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of gastrointestinal oncology, the Second People's Hospital of Lianyungang, Lianyungang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of gastrointestinal oncology, the Second People's Hospital of Lianyungang, Lianyungang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchang","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of gastrointestinal surgery, the Second People's Hospital of Lianyungang, Lianyungang"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"R1-20240318","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20240318","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3322\/caac.21220","article-title":"Colorectal cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R3-20240318","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(10)60353-4","article-title":"Colorectal cancer","volume":"375","author":"Cunningham","year":"2010","journal-title":"Lancet (London, England)"},{"key":"R4-20240318","first-page":"599","article-title":"NCCN guidelines updates: management of metastatic colorectal cancer","volume":"17","author":"Messersmith","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20240318","doi-asserted-by":"crossref","first-page":"e194489","DOI":"10.1001\/jamaoncol.2019.4489","article-title":"The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"issue":"(15_suppl)","key":"R6-20240318","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1200\/JCO.2019.37.15_suppl.3550","article-title":"Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies","volume":"37","author":"Salvatore","year":"2019","journal-title":"J Clin Oncol"},{"key":"R7-20240318","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s12094-019-02267-9","article-title":"Maintenance treatment in metastatic colorectal cancer: in search of the best strategy","volume":"22","author":"Ron","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"R8-20240318","doi-asserted-by":"crossref","first-page":"e18227","DOI":"10.1097\/MD.0000000000018227","article-title":"Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: a meta-analysis","volume":"98","author":"Ma","year":"2019","journal-title":"Medicine"},{"key":"R9-20240318","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdw101","article-title":"Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety","volume":"27","author":"Luo","year":"2016","journal-title":"Ann Oncol"},{"key":"R10-20240318","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/annonc\/mdw208","article-title":"Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients","volume":"27","author":"Cremolini","year":"2016","journal-title":"Ann Onco"},{"key":"R11-20240318","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-010-1322-0","article-title":"Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study","volume":"67","author":"Waddell","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R12-20240318","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.canlet.2017.02.034","article-title":"Metronomic chemotherapy in metastatic colorectal cancer","volume":"400","author":"Woo","year":"2017","journal-title":"Cancer Lett"},{"key":"R13-20240318","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2016.12.018","article-title":"Metronomic chemotherapy: a potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation","volume":"400","author":"Biziota","year":"2017","journal-title":"Cancer Lett"},{"key":"R14-20240318","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R15-20240318","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.canlet.2017.01.027","article-title":"Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: a phase II trial","volume":"400","author":"Montagna","year":"2017","journal-title":"Cancer Lett"},{"key":"R16-20240318","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.clcc.2019.03.002","article-title":"Metronomic capecitabine with cyclophosphamide regimen in unresectable or relapsed pseudomyxoma peritonei","volume":"18","author":"Raimondi","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"R17-20240318","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.5301\/tj.5000543","article-title":"Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study","volume":"103","author":"Cazzaniga","year":"2017","journal-title":"Tumori"},{"key":"R18-20240318","doi-asserted-by":"crossref","first-page":"42499","DOI":"10.1038\/srep42499","article-title":"Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study","volume":"7","author":"Casadei Gardini","year":"2017","journal-title":"Sci Rep"},{"key":"R19-20240318","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2018.12.028","article-title":"Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial","volume":"109","author":"Cremolini","year":"2019","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"R20-20240318","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3904\/kjim.2015.049","article-title":"Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients","volume":"32","author":"Jung","year":"2017","journal-title":"Korean J Intern Med"},{"key":"R21-20240318","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdv490","article-title":"A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial","volume":"27","author":"Hagman","year":"2016","journal-title":"Ann Oncol"},{"key":"R22-20240318","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12032-015-0496-z","article-title":"Continuous, low-dose capecitabine for patients with recurrent colorectal cancer","volume":"32","author":"Romiti","year":"2015","journal-title":"Med Oncol (Northwood, London, England)"},{"key":"R23-20240318","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"key":"R24-20240318","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"17","author":"Diaz-Rubio","year":"2012","journal-title":"Oncologist"},{"key":"R25-20240318","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet (London, England)"},{"key":"R26-20240318","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"key":"R27-20240318","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2017.75.2931","article-title":"Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9)","volume":"36","author":"Aparicio","year":"2018","journal-title":"J Clin Oncol"},{"key":"R28-20240318","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"R29-20240318","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2017.01.019","article-title":"Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer","volume":"75","author":"Franken","year":"2017","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"R30-20240318","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jamaoncol.2018.5070","article-title":"Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer","volume":"5","author":"Sherman","year":"2019","journal-title":"JAMA Oncol"},{"key":"R31-20240318","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrc1650","article-title":"Repopulation of cancer cells during therapy: an important cause of treatment failure","volume":"5","author":"Kim","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R32-20240318","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00262-015-1781-6","article-title":"A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Noguchi","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"R33-20240318","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.oraloncology.2014.12.002","article-title":"A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck","volume":"51","author":"Patil","year":"2015","journal-title":"Oral Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T11:13:03Z","timestamp":1710760383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":33,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023719","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}